On the morning of April 27, LEGEND Vascular Symposium 2024 was grandly held in Shanghai. At the meeting, the unblinded results of the anti-aging β-Nicotinamide Mononucleotide (short for NMN) , a human double-blind, randomized controlled clinical trial were announced: compared with the placebo, the physiological age of the NMN supplement group was significantly reduced!

This NMN clinical trial is a randomized, double-blind, placebo-controlled phase II clinical study. It is China's first NMN human clinical trial conducted in a Grade A tertiary hospital, marking that China's research on NMN has officially entered the clinical evidence-based stage.

The trial conducted a randomized double-blind controlled trial on people before taking NMN and after taking NMN, analyzed the impact of NMN on human aging markers, and recorded the regulation of transcription levels of genes related to aging, cell cycle, disease, etc. The test results showed that after the subjects took NMN (300mg/day) for 60 days, the levels of aging-related metabolites downstream of NMN in the blood increased significantly, and the physiological age was significantly reduced! 40% of the subjects said that their sleep quality improved after taking NMN, 30% of the subjects said that their appetite increased after taking NMN, 55% of the subjects said that their motor function improved after taking NMN, and 70% of the subjects said that they felt daily fatigue after taking NMN. Less than 60% of the subjects said that their daily blood pressure monitoring levels dropped after taking NMN, and 45% of the subjects said that their blood sugar monitoring levels dropped after taking NMN.